Cite
Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen
MLA
Wolf Herve Fridman, et al. “Increased Lymphocyte Infiltration in Patients with Head and Neck Cancer Treated with the IRX-2 Immunotherapy Regimen.” Cancer Immunology, Immunotherapy, vol. 61, Nov. 2011, pp. 771–82. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....996dd8a7e44868cbd583f46433a9fa2c&authtype=sso&custid=ns315887.
APA
Wolf Herve Fridman, Harvey Brandwein, Neil L. Berinstein, J. Michael White, Cécile Badoual, James E. Egan, Lorraine Baltzer, Lynn C. Goldstein, Adel K. El-Naggar, Theresa L. Whiteside, John W. Hadden, Paul H. Naylor, & Gregory T. Wolf. (2011). Increased lymphocyte infiltration in patients with head and neck cancer treated with the IRX-2 immunotherapy regimen. Cancer Immunology, Immunotherapy, 61, 771–782.
Chicago
Wolf Herve Fridman, Harvey Brandwein, Neil L. Berinstein, J. Michael White, Cécile Badoual, James E. Egan, Lorraine Baltzer, et al. 2011. “Increased Lymphocyte Infiltration in Patients with Head and Neck Cancer Treated with the IRX-2 Immunotherapy Regimen.” Cancer Immunology, Immunotherapy 61 (November): 771–82. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....996dd8a7e44868cbd583f46433a9fa2c&authtype=sso&custid=ns315887.